Milrinon Carino (Milrinone)

Milrinone, the active ingredient in Milrinon Carino, is a phosphodiesterase‑3 inhibitor presented as an intravenous solution for IV use. It is employed in the management of acute decompensated heart failure and cardiogenic shock in hospitalized patients.

GNH USA supplies Milrinon Carino as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Milrinone acts as a cardiac inotropic and vasodilating agent, targeting conditions characterized by reduced cardiac output. - Acute decompensated heart failure: improves cardiac output and relieves symptoms of fluid overload. - Cardiogenic shock: provides rapid inotropic support and systemic vasodilation to stabilize circulation. - Low cardiac output syndrome: enhances myocardial contractility to maintain adequate organ perfusion.

Milrinone may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Hypotension: decreased blood pressure after infusion. - Headache: mild to moderate intensity. - Nausea: gastrointestinal discomfort. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: reduced blood flow to heart muscle. - Severe allergic reaction: anaphylaxis or extensive skin rash.

Milrinone requires careful monitoring and specific safety measures before and during therapy. - Monitor blood pressure: watch for hypotension and adjust infusion rate as needed. - Observe cardiac rhythm: detect arrhythmias promptly. - Adjust dose in renal impairment: reduced clearance may increase exposure. - Use cautiously after recent myocardial infarction: risk of ischemia. - Avoid in uncontrolled arrhythmias: may exacerbate rhythm disorders. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Milrinone can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other phosphodiesterase‑3 inhibitors: additive inotropic effect may cause excessive stimulation. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase plasma milrinone concentrations. - Concurrent potent vasodilators (e.g., nitroglycerin): heightened risk of severe hypotension.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance hypotensive response. - Digoxin: combined use can increase the likelihood of arrhythmias.